Content Type: Article

  • HPE Miami 2023 | Current Issues and Trends in Purchase Agreement Negotiations and Rep & Warranty Insurance

    HPE Miami 2023 | Current Issues and Trends in Purchase Agreement Negotiations and Rep & Warranty Insurance

    ARTICLE

    HPE Miami 2023 | Current Issues and Trends in Purchase Agreement Negotiations and Rep & Warranty Insurance

    March 8-9, 2023

    Read time: 2 min

    Key takeaways
    Overview

    During this session, Gregory Metz, partner and co-head of McDermott’s Private Equity Practice Group, and Partner Michael McStay moderated a panel that discussed current issues and trends in purchase agreement negotiations and rep & warranty (R&W) insurance.

    Session panelists included:

    • Michael Constantinides, Principal, Revelstoke Capital Partners
    • Dan Skowronski, Principal, RiverGlade Capital
    • Joshua Halpern, Partner & Co-Practice Leader, Transaction Liability, Lockton Companies
    • Vipul Patel, Managing Director, Aon
    In depth

    Key takeaways included:

    1. Over the last six to nine months, it has become increasingly difficult to preempt auctions as buyer and seller valuation expectations have increasingly diverged.
    2. With the cost of debt financing increasing and availability decreasing, full equity back-stopped transactions have become increasingly compelling when deployed. Additionally, we are seeing an increased usage of rollover equity and seller notes to bridge the financing gap.
    3. While transaction volume is down, opportunities persist in healthcare consolidations, distressed asset sales and growth equity investments.
    4. The use of R&W insurance continues to be a beneficial strategy, easing the negotiation process between buyers and sellers and transferring risk to the insurance companies. We have seen more willingness on the part of sellers to pay for half or all of the R&W policy premiums. Lower deal volume, coupled with a drastic increase in the number of carriers in the marketplace over the last few years, has led to decreases in premiums, reduced retentions and broader coverage availability.
    Authors

    Gregory R. Metz

    Partner

    Chicago

    Michael P. McStay

    Partner

    Chicago

    More insights

  • HPE Miami 2023 | Distressed Investing: Where Are the Opportunities?

    HPE Miami 2023 | Distressed Investing: Where Are the Opportunities?

    ARTICLE

    HPE Miami 2023 | Distressed Investing: Where Are the Opportunities?

    March 8-9, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The final panel of HPE Miami 2023 focused on distressed investing in healthcare companies and the best ways to take advantage of opportunities (and avoid pitfalls) with such investments. Felicia Gerber Perlman, McDermott partner and global head of the Business Restructuring Practice Group, moderated the panel, which featured insights from:

    • Morris Alhale, Director, AlixPartners
    • Ari Lefkovits, Managing Director, Lazard
    • Frederic Levenson, Partner and Co-Head of Private Equity, McDermott Will & Emery
    • Zhe Zhao, Vice President, Oaktree Capital Management
    In depth

    Key takeaways included:

    1. The healthcare industry is currently experiencing various challenges and significant headwinds, including increased leverage, margin pressures and more than $20 billion of debt that will be due in the next three years. Due to these severe liquidity constraints, healthcare companies are looking for innovative ways to obtain additional capital, either from their existing lenders or from new financing sources in the market.
    2. Lenders have recently exhibited a renewed interest in providing additional capital to distressed healthcare companies, as long as there is a sufficient business justification for this “band-aid liquidity.” In other words, whether they are already involved with the distressed company or looking for a new potential investment opportunity, lenders want to understand how the additional capital will be used by the company. As such, transparency with any existing or potential lender about the intended uses for the requested funds is extremely important in order to maintain credibility and avoid issues obtaining financing in the future.
    3. There are different ways to take advantage of distressed opportunities in the healthcare industry, including by (1) implementing the transaction in court through a 363 sale or plan sponsor acquisition in Chapter 11 or (2) proceeding with the transaction out of court. The bankruptcy process provides certain benefits to a prospective buyer, including the ability to cherry-pick its desired assets, leave behind certain liabilities and select which contracts to assume or reject. However, investors are very aware that bankruptcy can be expensive and time-consuming. Developing a consensual deal structure with key constituents in advance of a Chapter 11 process can help minimize cost and time spent in bankruptcy, providing incentives for parties to “row in the same direction” and reach a consensus at the outset.
    4. In determining whether to invest in a distressed healthcare company, it is important to conduct sufficient diligence and analyze (1) existing and go-forward liquidity issues, as well as additional capital needs, (2) current liabilities and whether they can be disposed of, and (3) the company’s existing capital structure. Investors will want the restructured company to be successful on its own following the proposed transaction and “every dollar counts,” so understanding the company’s cash flow, liabilities and capital structure at the outset is essential. Additionally, healthcare is “a people business” at its core, and there is a certain standard of care that must be maintained regardless of how the transaction is implemented. As such, distressed investors must determine whether the company is able to maintain continuity of care for its patients both while the transaction is implemented and following consummation.
    5. It is critical for any potential investor to evaluate the distressed company’s existing management in order to determine whether to maintain the same team or bring in new management to fix existing issues. Analyzing how the company became distressed in the first place can facilitate this evaluation, including determining (1) whether there were missteps taken by current management, (2) whether current management can be trusted or properly incentivized to implement the proposed process successfully in good faith or (3) whether a new management team is necessary to facilitate the restructuring process.
    Authors
    More insights

  • Stryking Noncompete Preliminary Injunction

    Stryking Noncompete Preliminary Injunction

    ARTICLE

    Stryking Noncompete Preliminary Injunction

    Mar 9, 2023

    Read time: 5 min

    Key takeaways
    Overview

    The US Court of Appeals for the Sixth Circuit upheld a district court’s grant of a preliminary injunction restricting a former employee from working for conflicting organizations or communicating with a competitor’s counsel. Stryker Emp. Co., LLC v. Abbas, Case No. 22-1563 (6th Cir. Feb. 16, 2023) (Clay, Bush, JJ.; Sutton, C.J.) The Court found that the preliminary injunction was an appropriate measure to protect the plaintiff’s confidential information that was consistent with the employee’s noncompete agreement.

    Stryker develops and manufactures spinal implants and related medical products. From 2013 through mid-2022, Stryker employed Abbas in various roles relating to finance and sales. As part of his job duties, Abbas led sales and finance projects, assisted with Stryker’s litigation efforts, and cultivated relationships with customers, distributors and sales representatives. These responsibilities required Abbas to have access to Stryker’s confidential information and trade secrets.

    In April 2022, Abbas entered into a confidentiality, noncompetition and nonsolicitation agreement with Stryker. This agreement prohibited Abbas from disclosing Stryker’s confidential information without its consent and barred Abbas from working for “any Conflicting Organization” in which Abbas could use Stryker’s confidential information to boost the marketability of a “Conflicting Product or Service.” The noncompete provision was time limited to one year following Abbas’s departure from Stryker.

    In summer 2021, a competing spinal implant manufacturer, Alphatec, began recruiting Abbas for a finance position. After determining that the finance position was too similar to Abbas’s previous work at Stryker, Alphatec created a new “sales role” that was allegedly “crafted to protect Stryker’s confidential information.” Abbas resigned from Stryker in May 2022 to take the newly created role.

    Shortly after Abbas resigned, Stryker sued for breach of contract, misappropriation of trade secrets and violation of the Michigan Uniform Trade Secrets Act. Stryker also requested a no-notice temporary restraining order (TRO) and preliminary and permanent injunctions. The district court granted Stryker’s motion for preliminary injunction prohibiting Abbas from the following:

    • Working in any capacity for Alphatec or any “Conflicting Organization”
    • Having any ex parte communications with Alphatec’s counsel or otherwise disclosing information concerning Stryker’s litigation strategies.

    Abbas appealed, arguing that the noncompetition portion of the preliminary injunction amounted to an industry-wide ban and that the communication portion impermissibly disqualified counsel.

    The Noncompetition Provision

    The Sixth Circuit first noted that federal law, rather than state law, defines a court’s power to issue a noncompetition restriction in a preliminary injunction. Under federal law, courts have discretion to craft preliminary injunctions based on the equities of a case and can even “proscribe activities that, standing alone, would have been unassailable.” Applying this standard, the Sixth Circuit reasoned that the preliminary injunction was not overly broad but instead preserved the status quo. First, the district court found that Abbas often worked beyond the scope of his position. Second, the district court agreed to entertain a motion to vacate the injunction if Alphatec created a new position for Abbas that Stryker found acceptable. Third, the injunction merely sought to enforce the noncompetition agreement, which precluded Abbas from working for a competitor if the work was likely to result in the use of Stryker’s confidential information, or if the role would overlap with his previous job responsibilities. Because the injunction was consistent with the agreement and the district court was agreeable to modifying the order, the Sixth Circuit found no abuse of discretion.

    The Communication Provision

    The Sixth Circuit similarly concluded that the district court had not abused its discretion in prohibiting Abbas from communicating with Alphatec’s counsel. Stryker was involved in three other cases against Alphatec concerning former Stryker employees, and the district court found that Abbas “was privy to confidential information that if disclosed to Alphatec or Alphatec’s counsel, would detrimentally affect Stryker” in its other actions. The Court thus concluded that the communication prohibition was an appropriate measure to protect Stryker’s confidential information.

    The Preliminary Injunction Factors

    While Abbas did not directly address the four factors governing preliminary injunctive relief in his appeal, the Sixth Circuit did so, briefly noting the following:

    • Stryker was likely to prevail on its breach of contract claim because of the scope of Abbas’s job duties and his access to confidential information.
    • Stryker faced a threat of irreparable injury in the form of lost goodwill and competitive losses.
    • The equities favored Stryker, as Stryker was simply asking for its contract to be enforced.
    • The public interest lies in enforcing written contracts.

    Practice Note: In January 2023, the Federal Trade Commission proposed a ban on noncompete clauses, which it views as unfairly inhibiting employees’ ability to seek new employment opportunities. Stryker underscores the power of noncompetition agreements coupled with injunctive relief to prevent the misuse of confidential information before irreparable harm has been done. If the proposed ban is enacted, employers will only be able to seek redress for harm after the fact through trade secret litigation.

    Authors
    More insights
    Endnotes

  • HPE Miami 2023 | Fund Liquidity and Co-Investment Solutions

    HPE Miami 2023 | Fund Liquidity and Co-Investment Solutions

    ARTICLE

    HPE Miami 2023 | Fund Liquidity and Co-Investment Solutions

    March 8-9, 2023

    Read time: 6 min

    Key takeaways
    Overview

    During this session, Ian Schwartz moderated a panel that discussed how deteriorating financial conditions have put pressure on the ability to raise capital using traditional fund models while also putting a premium on much-needed liquidity. They also explored how general partners (GPs) are evolving in this environment by employing creative liquidity and co-investment solutions.

    Session panelists included:

    • Doug Brody, Partner & Head of Co-Investments and Partnerships, KKR Capital Markets
    • Raed Elkhatib, President & CEO, Atlantic-Pacific Capital
    • Tim Fitzsimmons, Managing Director, Lorient Capital
    • Binayak Mishra, Founding Partner, Dextra Partners
    • Tristram Perkins, Managing Director, Neuberger Berman
    • Ian Schwartz, Partner & Head of Investment Funds, McDermott Will & Emery (Moderator)
    In depth

    Key takeaways included:

    • We are in the midst of a highly challenging financial landscape, which has presented meaningful hurdles to capital raising. As a result, creative ideas have arisen that provide alternatives and/or complement the more traditional “blind pool” fund model. In particular, there has recently been a proliferation in the continuation fund market. GP-led deals and continuation funds have been used to drive momentum in a fundraiser. Now, these vehicles have become more mainstream standalone products offering high-performing assets that are being managed by established GPs and often are not tied directly to a “blind pool” fundraiser.
    • The last decade through the end of 2021 saw strong net cash flows for investors, with limited partners (LPs) receiving significantly more capital distributions than for capital calls on new investments. As exit activity slowed and initial public offering markets closed, this paradigm reversed beginning in 2022 and has resulted in substantial net outflows (approximately an $80 billion swing in net outflows.) While liquidity is at a premium as LPs experience a pronounced “denominator effect,” distributions derived from M&A exit activity have slowed because of a valuation gap between buyers and sellers. This scenario is well suited to solutions that may be achieved via GP-led transactions. Continuation funds, which represent about 85% of GP-led transactions, can be a viable alternative to a full exit for GPs. These structures allow GPs to offer a liquidity option to legacy investors while also providing for incremental capital to be raised to drive further growth of a portfolio company.
    • In addition to continuation vehicles, co-investment continues to be a large and growing segment of the GP-led marketplace. The approach to co-investing varies widely. On one end of the spectrum, there are more passive participants—mostly commonly funded LPs—that seek to average down their share of management and incentive fees. These investors frequently come in late when there is full certainty around the transaction details. At the other end of the spectrum, there are those investors that seek to serve as value-added participants, in some cases being involved in the diligence of the asset. In some cases, these groups serve as co-underwriters and/or become involved before there is even clarity on whether an investment will be consummated. Not many LPs or investors are willing or able to sit in the latter seat and, therefore, there can be significant value for this type of active investor.
    • Certain GPs are more concerned with how to keep investors involved in the business, either economically or as a contributor to the operations of the business. This is becoming a more complex situation as the cap table gets diversified with more investors, funds come with misaligned time horizons, the use of rollover equity, a longer-dated fund or a controlled investor that’s invested out of a new fund. The animating principle here is how to honor the duty to LPs to maximize value.
    • Liquidity alternatives such as continuation funds are available to all private equity funds but there is a particular relevance for healthcare. Some of the most relevant megatrends (value-based care, behavioral health, staffing, etc.) are issues that won’t be confronted for another three or five years, which is the typical holding period for a private equity investment, but are trends that will need solutions for the next 20 to 30 years. The calculus becomes this process of putting priority around generating returns and maximizing value for LPs and then thinking about how that plays into the series of liquidity solutions.
    • For healthcare infrastructure, which has extremely long-dated assets, it can be hard to find a good deal where one can add value. When a good opportunity is found, rather than selling a winner, some will want to continue to build that asset. Unlike public companies where the approach is typically to hold onto winners and let them run, with the fundraising cycle in private equity, you must sell your assets earlier in their life. Typically, such sales are of the strongest performing assets as opposed to when assets demonstrate performance return capital. The simple solution is to just have longer-dated funds; however, there is little market appetite from LPs for these longer-scale opportunities. Such lack of interest likely stems from LPs wanting another ability to underwrite the manager after a shorter period of time. The benefit seen in the continuation fund market is that rather than having to determine on day one whether there’s a massive compound over five, 10 or 15 years, you can actually make that decision down the road, say in three, five or even seven years.
    • Overall, we are moving toward a more bespoke market, and now more than in previous years, there is no “one-size-fits-all” approach. Tailored solutions in structuring the fundraising and lifecycle of private equity investments are necessary in today’s financial landscape.
    Authors

    Ian M. Schwartz

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • HPE Miami 2023 | Private Equity Fund Secondary Developments: Continuation Vehicles and Other GP-Led Transactions

    HPE Miami 2023 | Private Equity Fund Secondary Developments: Continuation Vehicles and Other GP-Led Transactions

    ARTICLE

    HPE Miami 2023 | Private Equity Fund Secondary Developments: Continuation Vehicles and Other GP-Led Transactions

    March 8-9, 2023

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Partner Erica Moscarello moderated a panel that discussed the increase in general practitioner (GP)-led secondary transactions and continuation funds.

    Session panelists included:

    • Christopher Areson, Partner, PJT Partners
    • Mike Custar, Managing Director, William Blair
    • David Solander, Partner, McDermott Will & Emery
    In depth

    Key takeaways included:

    1. While traditional limited partnership (LP) secondaries have historically dominated the market, the volume of continuation funds and other GP-led secondaries has increased significantly over the past few years as a way for fund sponsors to retain ownership of certain assets while providing liquidity to their limited partners, among other reasons. In 2022, the secondary market reported $110 billion in transaction size.
    2. GP-led transactions are attractive to management teams since they usually get some liquidity while avoiding the drawbacks of more traditional private equity exit routes (such as adapting to a new board in a third-party sponsor sale, possible redundancies in the case of a strategic sale and lockups and market volatility in the case of an initial public offering).
    3. Currently, the majority of lead investors in continuation funds are institutional fund-of-funds. However, the panelists anticipate that other types of limited partners will increasingly take a larger role in the continuation fund space.
    4. There are a number of special considerations with respect to continuation funds in the healthcare space due to the current healthcare regulatory environment.
    5. There are inherent conflicts of interest in continuation fund transactions since the portfolio companies are sold to an affiliate of the sponsor. Investors and the US Securities and Exchange Commission are increasingly focusing on conflict-of-interest issues in continuation fund transactions. Some of the methods sponsors use to deal with such conflicts of interest include, without limitation, being transparent with investors and obtaining a fair opinion.
    Authors

    Erica Moscarello

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • HPE Miami 2023 | Founder Success Stories and Lessons Learned

    HPE Miami 2023 | Founder Success Stories and Lessons Learned

    ARTICLE

    HPE Miami 2023 | Founder Success Stories and Lessons Learned

    March 8-9, 2023

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Curtis Lane, founding partner of MTS Health Partners, moderated a panel that collected insights from physician practice management (PPM) founders who partnered with private equity firms to expand their businesses and realize the full potential of their practices.

    Session panelists included:

    • Sulman Ahmed, DMD, Founder, Chairman & CEO, DECA Dental Group
    • Adam Elberg, Co-Founder & Managing Director, 3 Boomerang Capital
    • Deepak Kapoor, MD, Chairman & CECO, Solaris Health
    • Steven Madreperla, MD, PhD, President & CEO, PRISM Vision Group
    • Curtis Lane, Founding Partner, MTS Health Partners (Moderator)
    In depth

    Key takeaways included:

    1. PPM founders can retain independence and stay true to their vision for their medical practice while exponentially scaling their businesses by partnering with private equity funds.
    2. Private equity partners not only deliver financial and operational expertise to PPM businesses that doctors may not have organically, but these partnerships also lend founders the chance to diversify their net worth sources, which is often tied up exclusively in their practice.
    3. Private equity partners can also assist by connecting the practice in question with powerful board members and advisors, formalizing the practice’s books to ensure the full value of the practice is captured in its financials and providing expertise on corporate matters, such as determining the most efficient structures for expanding a medical practice geographically.
    4. Founders need not simply sell to their highest bidder; rather, founders should seek out private equity partners who understand and share in their vision for expansion while retaining independence. Founders should also lean on private equity partners to understand financial and creditor covenants.
    Authors
    More insights

  • HPE Miami 2023 | The Best Transaction for You: Different Deal Types and Structures

    HPE Miami 2023 | The Best Transaction for You: Different Deal Types and Structures

    ARTICLE

    HPE Miami 2023 | The Best Transaction for You: Different Deal Types and Structures

    March 8-9, 2023

    Read time: 2 min

    Key takeaways
    Overview

    During this session, the panelists discussed the various types of transaction structures and key considerations when building and executing an exit strategy.

    Session panelists included:

    • Brian Gordon, Partner, McDermott Will & Emery
    • Maria Navarro, Partner, McDermott Will & Emery
    • Patrick Rowe, Partner, McDermott Will & Emery
    • Nicole Schrumpf, Vice President, Jefferies & Company
    • Greg Weigand, Partner, McDermott Will & Emery
    In depth

    Key takeaways included:

    1. There is no one-size-fits-all approach for transaction structures. The nature of the buyer (i.e., private equity fund, strategic acquirer) will affect how a deal is structured.
    2. The best deal isn’t always about the best price. Buyers use a variety of tools to protect the value of their investment by keeping sellers involved with companies following closing. It’s important to consider who is taking over the company and whether they will be a good fit culturally, financially, etc.
    3. As for investment motivation, financial buyers typically seek to maximize return for their investors whereas a strategic buyer may be looking to increase market share, realize synergies or expand into new operational or geographical territories. These motivational differences play a large part in how a buyer operates a target following a sale.
    4. Depending on the goals of the buyer and the seller, as well as current market conditions, equity sales, asset sales, mergers or minority investments are all strategies parties should consider when entering into a transaction.
    Authors

    Brian M. Gordon

    Partner

    Atlanta

    Maria B. Navarro

    Partner

    Miami

    Gregory Weigand

    Counsel

    Miami, New York – One Vanderbilt Avenue

    More insights

  • HPE Miami 2023: Key Takeaways

    HPE Miami 2023: Key Takeaways

    ARTICLE / OTHER

    HPE Miami 2023: Key Takeaways

    March 8-9, 2023

    Read time: 5 min

    Key takeaways
    Overview

    HPE Miami 2023 was packed with unique panels and roundtable discussions where leading investors, bankers and industry experts provided their knowledge on the dynamic healthcare and private equity landscape. Check out the takeaways below for key insights regarding the challenging market, the latest developments in the industry and more.

     

    In depth

    Click on the links below to view key takeaways and presentations from HPE Miami 2023.

    Independent Healthcare Company Transactions Forum

    Preparing Your Company for a Transaction: Learn how to prepare your company for these important steps to optimize outcomes and mitigate risks.

    The Best Transaction for You: Different Deal Types and Structures: Discover how these different transaction types will help you maximize value and give you a clearer vision for your post-transaction life. | VIEW PRESENTATION 

    Assessing Market Conditions in the Current Economic Environment: Learn about valuable insider knowledge regarding favorable deal terms and how companies should best position themselves for success when in discussions with potential buyers.

    Founder Success Stories and Lessons Learned: Gain valuable insights from executives who have already partnered with a sponsor, including how they differentiated themselves from market competition, the evaluation process they undertook when determining the right next step for their companies.


    Private Equity Fund Sponsor & Investor Masterclass

    Private Equity Fund Secondary Developments: Continuation Vehicles and Other GP-Led Transactions: Discover structure, key points of negotiation and trends with respect to continuation funds and other GP-led secondary transactions.

    Fundraising in a Challenging Environment: Get an overview of the current market and insight into which strategies are yielding successful fundraising outcomes.

    Trends and Developments in Fund Finance: Oh My!: Learn about the latest in subscription capital call and NAV facilities, management fee facilities and management and executive lines of credit from lenders and investors on the front lines of fund financing trends. | VIEW PRESENTATION 


    Plenary Sessions

    2023: WTF? | What’s The (winning) Formula?: Find out what it takes to be successful in an area filled with landmines and opportunity and dealmaking predictions for 2023 and beyond.

    Strategies for Closing Healthcare Deals in Current Market Conditions: Discover how to seize opportunities in spite of recent complexities and navigate the headwinds, as well as what you should watch for when vetting potential investments.

    Fund Liquidity and Co-Investment Solutions: Explore how GP’s are evolving in this environment by utilizing creative liquidity and co-investment solutions.

    Financing Healthcare Companies in a Challenging Market: Dive into financing strategies for existing credits and new credits in the current market and uncover insights into specific challenges and opportunities for healthcare financings across the entire portfolio. | VIEW PRESENTATION 

    Getting Tactical: What Healthcare Investment Bankers Think: Find out what investment bankers at leading financial institutions predict for the year ahead, in particular as it impacts healthcare investing, a sector that has historically outpaced other industries during previous slumps.


    Roundtables

    Hot PPM Specialties: Spotlight on Cardiology, Ortho/PT and GI: Unpack how PPM expansion continues at a brisk clip as both financial and strategic investors pursue opportunities in many specialties, particularly cardiology, orthopedics/physical therapy and GI.

    Revolutionizing Healthcare with Value-Based Care: Examine the current market for value-based care companies and how investors can identify value-based care companies that will succeed over the long-term.

    Current Issues and Trends in Purchase Agreement Negotiations and Rep & Warranty Insurance: Discover top-of-mind issues in negotiating purchase agreement terms in today’s market.

    Digital Health Investing: Hot Areas for Innovative Healthcare Delivery: Learn about the latest developments in digital health and the critical inquiries to navigate the challenges and opportunities ahead.

    The Next Generation of PE and Hospital & Health System Collaboration: Dive into the how and why of the evolution of these partnerships and what the future holds for these creative deal structures.

    Buyer Beware: The Importance of Due Diligence in Healthcare Transactions: Review best practices for conducting thorough due diligence, including key healthcare risk areas and requirements, and the tools needed to make well-informed decisions.

    Tailwinds Impacting the Surge in Pharma Services Investing: Explore the tailwinds continuing to support pharma services and investment opportunities in this growing industry.

    Driving Behavioral Health to New Heights: Uncover the opportunities and challenges for investors in behavioral health businesses as well as a closer look at some data around the growth of the industry.

    Mitigating Risk & Liabilities: Strategies for 100 Days Post-Close and Beyond: Gain insight on the steps that investors can take to promote compliance as well as the roles, responsibilities and best practices for those serving in board roles, including strategies to mitigate risk, both for sponsors and portfolio companies.

    Distressed Investing: Where are the Opportunities?: Learn where and how to invest in healthcare companies to take advantage of the opportunities (or avoid the pitfalls) they present.

    Washington Insights: Expected Federal Health Policy and Reimbursement Changes in 2023: Discover how new Washington power plays will affect relevant payment policies for a variety of health services.

    Authors
    More insights

  • Healthcare Regulatory Check-up | January 2023

    Healthcare Regulatory Check-up | January 2023

    ARTICLE / REPORT

    Healthcare Regulatory Check-up | January 2023

    March 2023

    Read time: 2 min

    Overview

    This issue of McDermott’s Healthcare Regulatory Check-Up highlights significant regulatory activity and developments occurring in January 2023, including several criminal and civil enforcement actions related to the federal Anti-Kickback Statute (AKS), physician self-referral law (Stark Law) and False Claims Act (FCA). This issue also discusses recent regulatory developments more broadly.

    In depth
    Tabs

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    Dexter Golinghorst

    Associate

    Chicago

    More insights
    Endnotes

  • HPE Miami 2023 |  Assessing Market Conditions in the Current Economic Environment

    HPE Miami 2023 | Assessing Market Conditions in the Current Economic Environment

    ARTICLE

    HPE Miami 2023 | Assessing Market Conditions in the Current Economic Environment

    March 8-9, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Partner Andrea Zazulia moderated a panel during the Independent Healthcare Company Transactions Forum that focused on the ripple effects of recent market dynamics and the short- and long-term prognosis for healthcare transactions. Panelists included leading investment bankers who shared insights on current market trends and their impact on transaction considerations for the rest of 2023 and beyond.

    Session panelists included:

    • Steven Aguiar, Managing Director, Coker Capital
    • Henry Bloom, President, The Bloom Organization
    • Andrew Hewlett, Managing Director, B. Riley Securities
    • Porter Meadors, Director, Brentwood Capital Advisors
    • John Riddle, Managing Director, Brown Gibbons Lang & Company
    In depth

    Key takeaways included:

    1. Creative Deal Structures Given Today’s Debt Market: Buyers and sellers have proceeded with caution over the last few quarters given the fluctuation of interest rates and limited availability of debt financing. Although the hesitancy of debt providers and the uncertainty surrounding interest rates has made it harder to transact, deals have not stopped altogether, and the market is still hot for the right targets. Parties are finding innovative ways to address valuation issues, including the use of seller notes, earnouts and creative structures that are beneficial to all stakeholders.
    2. Hot Subsectors in the Current Market Dynamics: Changes in market dynamics are creating opportunities for new healthcare subsectors and driving sponsors to diversify their platforms. The healthcare services market continues to be a complex, multifaceted industry that encompasses a broad range of services, and the current environment has enabled certain pockets of the industry to experience significant growth. For example, the panelists shared that sponsors who previously transacted exclusively in the physician practice management space are now diversifying and investing in other subsectors. This has led to a significant increase in transactions in health IT, pharmaceutical services and technology-driven healthcare services, including revenue cycle management, educational training and staffing. Transformative transactions are indicative of—and a further driver for—rethinking healthcare, including as a great deal of optionality for investors.
    3. The Healthcare Market Continues to Grow: The panelists all agreed that healthcare will continue to be a strong sector moving forward. Even in the current market, there are still significant opportunities, including substantial activity and high multiples in the pharmaceutical space, particularly in connection with any post-approval market strategy or consulting services. The panelists anticipate an extremely strong second half of the year for healthcare services generally and believe the market will begin to feel crowded again for physician platforms as debt markets begin to settle down.
    4. Preparing for a Sale: The panelists indicated that in the current conditions, companies must be adequately prepared prior to going to market in order to get a deal across the finish line. The panelists also stressed that any company looking to sell in the next 12 to 18 months should begin preparing for the transaction process now and ensure that they are aligned with their advisors. Organizations that do not spend enough time preparing for a transaction and understanding key value drivers often experience significant issues. Steps companies can take to best position themselves for a potential sale include (1) ensuring the company is clean from a compliance and financial perspective, (2) conducting billing and coding audits (as applicable) and completing the Quality of Earnings process early, and (3) getting ahead of any potential or known issues, including addressing any labor storages or other areas of concern that may come up in the due diligence process. Companies should also consult with tax and accounting advisors regarding the organization’s current structure and take any restructuring steps necessary prior to going to market.
    Authors

    Andrea Zazulia

    Partner

    Miami

    More insights